200 PINE STREET SUITE 400, SAN FRANCISCO, CA
Reports 2025 Financials
Jaguar Health Enters Amendment to Uptown 2020 Royalty Interest Agreement
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Special Dividend Declared; Series O Preferred Stock Issued
Risk Factors
Jaguar Health Enters Iliad Royalty Interest Exchange Agreement
Enters into U.S. License Agreement for Crofelemer, Providing up to $38 Million
Jaguar Health, Inc. Enters $350,000 Securities Purchase Agreement
FY 2025
Notice of Late Filing for Annual Report
Q3
Q2
Q1
Amended Annual Report
FY 2024
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Notice of Exempt Offering of Securities
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(5)
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report
Submission Upload
Correspondence